In cancer immunotherapy, the capabilities of CRISPR/Cas9 extend to the tumor microenvironment, and one of the main approaches in CRISPR-based cancer immunotherapy is to target the PD-1/PD-L1 pathway in cancer cells [19,62]. Here, PDCD1 is linked to neoplasm.